Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody - PubMed (original) (raw)
. 2013 May 31;340(6136):1113-7.
doi: 10.1126/science.1234914. Epub 2013 Apr 25.
Man Chen, Sherman Leung, Kevin W Graepel, Xiulian Du, Yongping Yang, Tongqing Zhou, Ulrich Baxa, Etsuko Yasuda, Tim Beaumont, Azad Kumar, Kayvon Modjarrad, Zizheng Zheng, Min Zhao, Ningshao Xia, Peter D Kwong, Barney S Graham
Affiliations
- PMID: 23618766
- PMCID: PMC4459498
- DOI: 10.1126/science.1234914
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
Jason S McLellan et al. Science. 2013.
Abstract
The prefusion state of respiratory syncytial virus (RSV) fusion (F) glycoprotein is the target of most RSV-neutralizing activity in human sera, but its metastability has hindered characterization. To overcome this obstacle, we identified prefusion-specific antibodies that were substantially more potent than the prophylactic antibody palivizumab. The cocrystal structure for one of these antibodies, D25, in complex with the F glycoprotein revealed D25 to lock F in its prefusion state by binding to a quaternary epitope at the trimer apex. Electron microscopy showed that two other antibodies, AM22 and 5C4, also bound to the newly identified site of vulnerability, which we named antigenic site Ø. These studies should enable design of improved vaccine antigens and define new targets for passive prevention of RSV-induced disease.
Figures
Figure 1. RSV neutralization, F glycoprotein recognition, and crystal structure of human antibody D25 in complex with the prefusion RSV F trimer
The prefusion conformation of RSV F is metastable, and when expressed in a soluble form readily adopts the postfusion state; a number of potent antibodies, including D25, bind to a newly revealed antigenic site at the top of the prefusion F glycoprotein. (A) RSV neutralization by antibodies. Palivizumab is the FDA-approved prophylactic antibody that prevents severe RSV disease. (B) ELISA measuring antibody binding to postfusion F glycoprotein. For (A) and (B), data are representative of multiple independent experiments. (C) D25-RSV F trimer crystal structure in ribbon and molecular surface representations. One protomer of the F glycoprotein trimer is shown as ribbons and colored as a rainbow from blue to red, N-terminus of F2 to C-terminus of F1, respectively. Molecular surfaces are shown for the other two F protomers, colored pink and green. The D25 Fab bound to the F protomer shown in ribbons is also displayed in ribbon representation, with heavy chain colored red and light chain colored grey. The other D25 Fabs are colored the same, but shown in surface representation.
Figure 2. Structural rearrangement of RSV F
To mediate virus-cell entry, the RSV F glycoprotein transitions from a metastable prefusion conformation to a stable postfusion conformation. Outer images display prefusion (left) and postfusion (right) trimeric structures, colored the same as in Fig. 1C. A complex glycan, shown as sticks, is modeled at each of the three _N_-linked glycosylation sites found in the mature protein. Inner images display a single RSV F protomer in ribbon representation, colored as a rainbow from blue to red, N-terminus of F2 to C-terminus of F1, respectively. Select secondary structure elements are labeled (correspondence with amino acid sequence in pre- and postfusion conformations is shown in fig. S3). Inset: schematic of the mature RSV F protein in the RSV F(+) Fd construct. The rainbow coloring of the boxes representing the F2 and F1 subunits matches that in the structures. Glycans are shown as branches on top of the boxes, and disulfide bonds are shown as black lines under the boxes. Amino acids that move more than 5 Å in the pre- and post-fusion conformations are indicated by black bars.
Figure 3. RSV F interface with D25
Antibody D25 binds a quaternary epitope spanning two protomers at the apex of the prefusion F trimer. (A) Close-up of the interface between D25 and RSV F. Side chains of F residues interacting with D25 are labeled and shown as sticks. Oxygen atoms are colored red and nitrogen atoms are colored blue. Hydrogen bonds are depicted as dotted lines. The two images are related by a 90° rotation about the vertical axis. (B) Position and conformation of the D25 epitope on the prefusion and postfusion F molecules. RSV F residues at the D25 interface are colored red; polarity of α4 and α5post indicated with arrows, with fragment N- and C-termini indicated. (C) Surface representation of RSV F colored according to sequence conservation. Coloring was generated using the ConSurf server (40) using 178 F glycoprotein sequences from human RSV subtype A and B, as well as bovine RSV. (D) Sequence conservation of F residues in regions recognized by D25. Amino acids in human RSV subtype B (hRSV/B) or in bovine RSV (bRSV) that differ from hRSV/A are colored red. Ectodomain is defined as F residues 26-109 and 137-524.
Figure 4. Antigenic site Ø
Highly effective RSV-neutralizing antibodies target a site at the membrane-distal apex of the prefusion F trimer. (A) The ability of antibodies to block D25 binding to RSV-infected cells was measured as a function of antibody concentration. (B) Analysis of RSV F-Fab complexes by negative stain electron microscopy: Reprojection of a 12 Å slice through the crystal structure of RSV F + D25 Fab filtered to 10 Å resolution (left). A slice was used to emphasize visibility of the F glycoprotein cavity. Aligned average of 263 particles of RSV F + D25 Fab (middle - left). Aligned average of 550 particles of RSV F + AM22 Fab (middle - right). Aligned average of 171 particles of RSV F + 5C4 Fab (right). Scale bar is 50 Å. (C) Fusion inhibition and (D) attachment inhibition activity for antibodies targeting antigenic site Ø and F-specific antibodies targeting other antigenic sites. For the attachment-inhibition assay, heparin was used as a positive control. Data in panels (A) (C) and (D) are representative of multiple independent experiments.
Similar articles
- Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.
Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS. Zhao M, et al. J Virol. 2017 Jul 12;91(15):e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1. J Virol. 2017. PMID: 28539438 Free PMC article. - Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. Swanson KA, et al. Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. doi: 10.1073/pnas.1106536108. Epub 2011 May 17. Proc Natl Acad Sci U S A. 2011. PMID: 21586636 Free PMC article. - Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE Jr. Mousa JJ, et al. Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6849-E6858. doi: 10.1073/pnas.1609449113. Epub 2016 Oct 17. Proc Natl Acad Sci U S A. 2016. PMID: 27791117 Free PMC article. - Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.
McLellan JS. McLellan JS. Curr Opin Virol. 2015 Apr;11:70-5. doi: 10.1016/j.coviro.2015.03.002. Epub 2015 Mar 26. Curr Opin Virol. 2015. PMID: 25819327 Free PMC article. Review. - Novel antigens for RSV vaccines.
Graham BS, Modjarrad K, McLellan JS. Graham BS, et al. Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Curr Opin Immunol. 2015. PMID: 26070108 Free PMC article. Review.
Cited by
- Enhanced Staphylococcus aureus protection by uncoupling of the α-toxin-ADAM10 interaction during murine neonatal vaccination.
Tomaszewski KL, Blanchard M, Olaniyi R, Brenton HR, Hayes S, Fatma F, Amarasinghe GK, Cho BK, Goo YA, DeDent AC, Fritz SA, Wardenburg JB. Tomaszewski KL, et al. Nat Commun. 2024 Oct 8;15(1):8702. doi: 10.1038/s41467-024-52714-7. Nat Commun. 2024. PMID: 39379345 - Global progress in clinical research on human respiratory syncytial virus vaccines.
Peng R, Chen C, Chen Q, Zhang Y, Huang R, Zhang Y, Li J. Peng R, et al. Front Microbiol. 2024 Sep 2;15:1457703. doi: 10.3389/fmicb.2024.1457703. eCollection 2024. Front Microbiol. 2024. PMID: 39286350 Free PMC article. Review. - Systematic computer-aided disulfide design as a general strategy to stabilize prefusion class I fusion proteins.
Gonzalez KJ, Yim KC, Blanco JCG, Boukhvalova MS, Strauch EM. Gonzalez KJ, et al. Front Immunol. 2024 Jul 24;15:1406929. doi: 10.3389/fimmu.2024.1406929. eCollection 2024. Front Immunol. 2024. PMID: 39114655 Free PMC article. - Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer.
Bakkers MJG, Ritschel T, Tiemessen M, Dijkman J, Zuffianò AA, Yu X, van Overveld D, Le L, Voorzaat R, van Haaren MM, de Man M, Tamara S, van der Fits L, Zahn R, Juraszek J, Langedijk JPM. Bakkers MJG, et al. Nat Commun. 2024 Jul 25;15(1):6270. doi: 10.1038/s41467-024-50659-5. Nat Commun. 2024. PMID: 39054318 Free PMC article.
References
- Glezen W, Taber L, Frank A, Kasel J. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986;140:543. - PubMed
- Shay DK, et al. Bronchiolitis-Associated Hospitalizations Among US Children, 1980–1996. JAMA. 1999;282:1440. - PubMed
- Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997;176:1215. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous